Evidence map›Paper›PMID 34935434›Full record

ArticleJournal of virology2022

A Hybrid Soluble gp130/Spike-Nanobody Fusion Protein Simultaneously Blocks Interleukin-6

Julia Ettich, Julia Werner, Hendrik T Weitz, Eva Mueller, Roland Schwarzer, Philipp A Lang, Jürgen Scheller, Jens M Moll

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Julia EttichInstitute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Julia WernerDepartment of Molecular Medicine II, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Hendrik T WeitzInstitute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Eva MuellerInstitute for Translational HIV Research, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Roland SchwarzerInstitute for Translational HIV Research, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Philipp A LangDepartment of Molecular Medicine II, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Jürgen SchellerInstitute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Jens M MollInstitute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.ORCID 0000-0003-3508-5828
Heinrich Heine University Düsseldorf · DEUniversity of Duisburg-Essen · DE

Funding

Deutsche Forschungsgemeinschaft (DFG) SFB974
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can induce mild to life-threatening symptoms. Especially individuals over 60 years of age or with underlying comorbidities, including heart or lung disease and diabetes, or immunocompromised patients are at a higher risk. Fatal multiorgan damage in coronavirus disease 2019 (COVID-19) patients can be attributed to an interleukin-6 (IL-6)-dominated cytokine storm. Consequently, IL-6 receptor (IL-6R) monoclonal antibody treatment for severe COVID-19 cases has been approved for therapy. High concentrations of soluble IL-6R (sIL-6R) were found in COVID-19 intensive care unit patients, suggesting the involvement of IL-6

Indexed as

COVID-19COVID-19 Drug TreatmentCytokine Receptor gp130Recombinant Fusion ProteinsSingle-Domain AntibodiesAnimalsChlorocebus aethiopsHumansInterleukin-6Signal TransductionSpike Glycoprotein, CoronavirusVero CellsCytokine Receptor gp130IL6 protein, humanInterleukin-6Recombinant Fusion ProteinsSingle-Domain AntibodiesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2IL-6SARS-CoV-2sgp130trans-signaling

Identifiers

PMID34935434
PMCPMC8865451
OpenAlexW4200219418

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.